Innovate Biopharmaceuticals, Inc. (INNT) Company Bio
Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. Its late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease (IBD), and nonalcoholic steatohepatitis (NASH). The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease. It is also developing INN-108, which is entering into Phase 2 clinical trials for the treatment of mild to moderate ulcerative colitis. In addition, the company owns the global rights to INN-329, a proprietary formulation of secretin, a peptide hormone used to enhance visualization in magnetic resonance cholangiopancreatography procedures. Innovate Biopharmaceuticals, Inc. was founded in 2012 and is based in Raleigh, North Carolina.